Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 299,396 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on February 20, 2007, and was notified to the company on February 21, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a share transfer executed by Abacus (GSK) Trustees Limited as trustee of the GSK Trust, a discretionary trust for current and former employees.
Key Facts for Investor Verification
- Transaction Type: Transfer of Ordinary Shares from the GSK Trust to employee plan participants.
- Volume: 299,396 shares transferred.
- Directors Involved: Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees.
- Regulatory Basis: Notification made in accordance with Disclosure Rule 3.1.4R(1)(b).